Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece

Clinical Drug Investigation

Volumn 36, Issue 8, 2016, Pages 649-659

  Tzanetakos, Charalampos ^a   Tentolouris, Nicholas ^b   Kourlaba, Georgia ^c   Maniadakis, Nikos ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; DAPAGLIFLOZIN PLUS METFORMIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; INSULIN GLARGINE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; VILDAGLIPTIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; ARTICLE; BLINDNESS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETIC PATIENT; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; END STAGE RENAL DISEASE; FEMALE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; GREECE; HEALTH CARE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INCREMENTAL COST EFFECTIVENESS RATIO; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROBABILITY; PROBABILITY SENSITIVITY ANALYSIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SIDE EFFECT; SIMULATION; STATISTICAL PARAMETERS; UNCERTAINTY; UNIVARIATE ANALYSIS; URINARY TRACT INFECTION; AGED; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; COMPLICATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMIC MODEL; ECONOMICS; TREATMENT OUTCOME;

AGED; BENZHYDRYL COMPOUNDS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; GREECE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84969939855     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-016-0410-2     Document Type: Article

References (42)

1. Gikas A, Sotiropoulos A, Panagiotakos D, et al. Rising prevalence of diabetes among Greek adults: findings from two consecutive surveys in the same target population. Diabetes Res Clin Pract. 2008;79:325–9.
2. Migdalis I, Rombopoulos G, Hatzikou M, et al. The cost of managing type 2 diabetes mellitus in Greece: a retrospective analysis of 10-year patient level data “The HERCULES Study”. Int J Endocrinol. 2015;2015:7.
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–79.
4. Hellenic Diabetes Association. Management guidelines for a diabetic patient. Available from: http://www.ede.gr/. Accessed 15 Sept 2015.
5. Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297–322.
6. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab. 2010;12:623–30.
7. The Mount Hood, 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care. 2007;30:1638–46.
8. Palmer AJ, Clarke P, Gray A, et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health. 2013;16:670–85.
9. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–59.
10. Hayes AJ, Leal J, Gray AM, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56:1925–33.
11. McEwan P, Ward T, Bennett H, et al. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Eff Resour Alloc. 2015;13:12.
12. World Health Organization (WHO). Greece life tables. Available from: http://apps.who.int/gho/data/view.main.60640. Accessed 12 Sept 2015.
13. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. April 2013. Available from: https://www.nice.org.uk/article/pmg9/chapter/Foreword. Accessed 12 Sept 2015.
14. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–22.
15. Barnett AH, Orme ME, Fenici P, et al. Systematic review and network meta-analysis to compare dapagliflozin with other diabetes medications in combination with metformin for adults with type 2 diabetes. Intern Med. 2014;S6:S6–006.
16. Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014;16:433–42.
17. Liatis S, Thomakos P, Papaoikonomou S, et al. Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 and 2006). Exp Clin Endocrinol Diabetes. 2009;117:505–10.
18. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184–9.
19. Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of type 2 diabetes mellitus. Diabet Med. 2015;32:890–8.
20. Charokopou M, McEwan P, Lister S, et al. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to metformin in the treatment of type 2 diabetes mellitus from a UK Healthcare System perspective. BMC Health Serv Res. 2015;15:496.
21. Sabale U, Ekman M, Granstrom O, et al. Cost-effectiveness of dapagliflozin (Forxiga(R)) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2015;9:39–47.
22. van Haalen HG, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34:135–46.
23. Nauck MA, Del Prato S, Duran-Garcia S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16:1111–20.
24. Del Prato S, Nauck M, Duran-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17:581–90.
25. Greek Ministry of Health. Drug price bulletin. Available from: http://www.moh.gov.gr/. Accessed 10 June 2015.
26. National Organization for Healthcare Services Provision [EOPYY] official website. Available from: www.eopyy.gov.gr. Accessed 10 June 2015.
27. Government Gazette. Common Ministerial Decree. FEK 1561B’/21-06-2013.
28. Tzanetakos C, Melidonis A, Verras C, et al. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res. 2014;14:419.
29. Papazafiropoulou AK, Kardara MS, Bousboulas S, Pappas SI. Cost of hospitalization for hypoglycemia among subjects with type 2 diabetes. Arch Hell Med. 2013;30:628–9.
30. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22:340–9.
31. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010;14:1–248.
32. Granstrom O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012;6:127–36.
33. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26.
34. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14:217–30.
35. Lane S, Levy AR, Mukherjee J, et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30:1267–73.
36. World Health Organization (WHO). Choosing interventions that are Cost Effective (WHO-CHOICE): Cost-effectiveness thresholds. Available from: http://www.who.int/choice/en/. Accessed 15 Sept 2015.
37. International Monetary Fund (IMF). World Economic Outlook Database. Available from: http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx. Accessed 15 Sept 2015.
38. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57:455–60.
39. Fox KM, Gerber Pharmd RA, Bolinder B, et al. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther. 2006;28:388–95.
40. Bodegard J, Sundstrom J, Svennblad B, et al. Changes in body mass index following newly diagnosed type 2 diabetes and risk of cardiovascular mortality: a cohort study of 8486 primary-care patients. Diabetes Metab. 2013;39:306–13.
41. Cummins E, Scott N, Rothnie K, et al. Dapagliflozin for the treatment of type 2 diabetes. Aberdeen: Aberdeen HTA Group, Institute of Applied Health Sciences, University of Aberdeen; 2012.
42. Charokopou M, Sabater FJ, Townsend R, et al. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. Curr Med Res Opin. 2016;32:207–18.